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Abstract We report two children with hemolytic anemia
during the course of hepatitis A infection. On admission,
the patients had high blood urea nitrogen, creatinine, and
uric acid levels, as well as anemia, leucocytosis, and direct
and indirect hyperbilirubinemia. Both patients had a
glucose-6-phosphate dehydrogenase deficiency (G6PD)
and autoimmune antibodies. They were given vitamin K
on admission. Inadvertent administration of vitamin K
could have been related to an acute reduction in hemoglo-
bin concentration. To prevent renal damage, plasmapheresis
with fresh frozen plasma was done to clear bilirubin and
plasma hemoglobin. The hyperbilirubinemia responded to
plasmapheresis. However, acute tubular necrosis compli-
cated the clinical course in one patient, and several sessions
of hemodialysis were required. In conclusion, intravascular
hemolysis should be considered in patients with hepatitis A
infection, marked hyperbilirubinemia, and anemia. Al-
though hepatitis A vaccination is not yet recommended for
routine administration, high-risk patients, including those
with a G6PD deficiency, should be vaccinated against
hepatitis A.
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antidsDNA Antidouble-stranded deoxyribonucleic acid
BUN Blood urea nitrogen
Cr Creatinine
G6PD Glucose-6-phosphate dehydrogenase deficiency
Hb Hemoglobin
LDH Lactate dehydrogenase
SMA Smooth muscle antibody
WBC White blood cell
Introduction
A variety of extrahepatic manifestations (e.g., acalculous
cholecystitis, acute pancreatitis, glomerulonephritis, pleural
or pericardial effusion, acute reactive arthritis, neurologic
disorders, and hemolytic anemia) can be observed in
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patients with acute hepatitis A infection. The pathogenic
mechanism of hemolytic anemia during hepatitis A infec-
tion has not been elucidated completely. Hemolytic anemia
could be associated with shortened red cell survival, or it
might be autoimmune in nature [12, 15]. Massive hemoly-
sis has been reported in patients with infection with
hepatitis A, B, or E viruses and a concomitant glucose-6-
phosphate dehydrogenase (G6PD) deficiency [1, 10].
G6PD deficiency and hepatitis A virus infection are
common in patients in Mediterranean countries, and the
presence of viral hepatitis A and G6PD deficiency in the
same patient therefore would be expected.
Two studies done in two different regions of Turkey
show that the prevalence of G6PD deficiency is high,
reaching up to 10% in some ethnic populations (the normal
range is 3%-8%) [2, 3]. The G6PD enzyme catalyzes the
oxidation of glucose and maintains glutathione in its
reduced form [5]. In patients with a G6PD deficiency, this
enzyme is deficient in liver cells as well as in erythrocytes.
It has been suggested that this deficit may prevent the repair
of hepatocytes damaged by viral hepatitis and, as a result of
increased oxidative damage to hepatocytes because of
glutathione depletion, may increase liver damage [9].
Patients with infection with acute viral hepatitis A and a
concomitant G6PD deficiency have a statistically signifi-
cantly prolonged prothrombin time, a higher temperature,
and elevated leukocyte counts and mean serum bilirubin
levels (including direct bilirubin) [9].
Here, we report two children with hemolytic anemia
during the course of hepatitis A infection. Both had a G6PD
deficiency and autoimmune antibodies. We discuss the
etiology of acute severe hemolysis and describe our
management of intravascular hemolysis, severe hyperbilir-
ubinemia, hepatic encephalopathy, and acute renal failure in
these patients.
Patient 1
A 10-year-old previously healthy boy with a 4-day history
of jaundice, fatigue, vomiting, and abdominal pain that
radiated to his back was transferred to our hospital. A
diagnosis of hepatitis A had been made in another hospital.
This patient had no history of liver disease or a hereditary
blood disease, exposure to a toxic agent, recent treatment
with medication, or recent ingestion of fava. On physical
examination, because of severe abdominal pain, the patient
was in the chest-knee position. He appeared weak, but was
conscious. He was severely jaundiced. Tenderness to
palpation with rebound in the right upper quadrant and
epigastrium was noted, as was hepatomegaly with a liver
span of 2 cm. The spleen was 2 cm below the subcostal
margins at the midclavicular line.
The results of laboratory testing on admission were as
follows (expected ranges in parenthesis): hemoglobin (Hb),
8.5 g/dl (12–15); white blood cell count (WBC), 26.1×
109/l (4.5–11×109/l); mean corpuscular hemoglobin, 31.7 pg
(25–34); mean corpuscular volume, 90.7 fl (75–95); platelet
count, 329×109/l (150–400×109/l); blood urea nitrogen
(BUN), 33 mg/dl (6–21); creatinine, 0.75 mg/dl (0.5–1); uric
acid, 9.9 mg/dl (2–5.8); aspartate aminotransferase, 8,943 U/
l (0–40); alanine aminotransferase, 6,880 U/l (0–41); gamma
glutamyl transferase, 156 U/l (18–61); alkaline phosphatase,
291 U/l (100–250); total bilirubin, 52.41 mg/dl (0–1.2); direct
bilirubin, 32.12 mg/dl (0–0.3); ammonia, 70 μmol/l (14.7–
55.3); lactate, 5.4 mmol/l (0.7–2.1); prothrombin time, 18.9 s
(11–15); international normalized ratio, 1.56 (1–1.2); fibrin-
ogen, 207 mg/dl (200–400). A peripheral blood smear
showed 48% neutrophils, 24% metamyelocytes, 6% myelo-
cytes, 19% lymphocytes, and 3% monocytes. Seven percent
of normoblasts with fragmented erythrocytes and diffuse
spherocytes also were seen (Table 1).
Initially, the patient was rehydrated and received supportive
care that included maintaining the fluid-electrolyte balance. He
was treated with intravenous cefotaxime because of his high
fever and leukocytosis; vitamin K (5 mg) was administered
intravenously. Eight hours later, his overall condition had
deteriorated, and his hemoglobin level decreased to 5.1 g/dl.
His urine was dark brown. His reticulocyte count was 6.75%
(normal range, 0.5%-1.5%), and his haptoglobulin level was
4 mg/dl (normal range, 30–300 mg/dl). The results of direct
and indirect Coombs’ tests and erythrocyte osmotic fragility
tests were negative, and the results of hemoglobin electro-
phoresis were within the normal range. His serum iron level
was 224 μg/dl (normal range, 60–170 μg/dl), his serum
iron-binding capacity was 2 μg/dl (normal range, 130–
350 μg/dl), and his ferritin level was 1,274 ng/dl (normal
range, 20–200 ng/dl). His lactate dehydrogenase level was
5979 U/l (normal range, 180–430 U/l). The results of a urine
analysis showed hemoglobinuria without erythrocytes. The
results of an assay for G6PD showed a low level of enzymatic
activity (1.34 U/g Hb; normal range, 4.6–13.5 U/g Hb). G6PD
activity was determined by the kinetic (ultraviolet) method
(Sigma Diagnostic, Germany). Hepatitis B, C, D, and E
viruses, Cytomegalovirus, Epstein-Barr virus, human immu-
nodeficiency virus, parvovirus B 19, herpes simplex virus
types 1 and 2, toxoplasmosis, and rubella infection were ruled
out by the results of serologic assays. The results of testing
for serum hepatitis A virus immunoglobulin G and immuno-
globulin M antibodies were positive. The patient was
diagnosed as having viral hepatitis A, and hemolytic anemia.
The results of testing for antinuclear antibody (ANA) (1/40),
smooth muscle antibody (SMA) (1/40), and antidouble-
stranded deoxyribonucleic acid (antidsDNA; 75.3 U/ml
(normal range, 0–25 U/ml)) were positive. The patient required
repeated blood transfusions because of his progressive anemia.
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Although he was adequately hydrated and alkalized, his
serum BUN and creatinine levels increased to 51 mg/dl and
1.45 mg/ dl, respectively. His urine output decreased to less
than 500 ml/day. To prevent renal damage, plasmapheresis
with fresh frozen plasma was performed three times for the
clearance of bilirubin and plasma hemoglobin. The hyper-
bilirubinemia responded to plasmapheresis. However, acute
tubular necrosis complicated the clinical course because
several sessions of hemodialysis were required. The patient
was discharged from the hospital 1 month after his admission,
at which time the values of his liver and kidney functions were
almost within their respective normal ranges. Two months
later, the results of tests for ANA, SMA, and antidsDNAwere
negative. His hemoglobin level was normal.
Patient 2
A 5-year-old girl with encephalopathy, vomiting, icterus,
and fever for 3 days was admitted to our hospital for
treatment. She had taken no medication and had not
ingested fava. Her brother had been diagnosed as having
acute hepatitis A infection. At the time of her physical
examination, she was stuporous and her temperature was
38°C. Her sclerae were icteric, her liver was palpable 1 cm
below the subcostal margins at the midclavicular line, and
her spleen was not palpable. The results of laboratory
studies performed at the patient’s admission were as follows
(expected ranges in parenthesis): Hb, 9.8 g/dl (12–15);
WBC, 23.9×109/l (4.5–11×109/l); mean corpuscular hemo-
globin, 26 pg (25–34); mean corpuscular volume, 81 fL
(75–95); platelet count, 751×109/l (150–400×109/l; glucose,
111 mg/dl (60–100); aspartate aminotransferase, 1,157 U/l
(0–40); alanine aminotransferase, 1,601 U/l (0–41); alkaline
phosphatase, 256 U/l (100–250); gamma glutamyl transferase,
54 U/l (18–61); total bilirubin, 48 mg/dl (0–1.2) with a direct
fraction of 31 mg/dl (0–0.3); BUN, 46 mg/dl (6–21);
creatinine, 1.6 mg/dl (0.5–1); uric acid, 10.7 mg/dl (2–5.8);
ammonia, 256 μmol/l (14.7–55.3); lactate dehydrogenase,
1,570 U/l (180–430); prothrombin time, 18.5 s (11–15);
international normalized ratio, 1.59. The results of tests for
serum levels of copper, ceruloplasmin, alfa-1 antitrypsin,
ANA, and antidsDNA were negative, and the test result for
SMAwas positive (1/80). The results of serologic testing for
hepatitis B, C, D, and E viruses, Toxoplasma gondii, rubella,
Epstein-Barr virus, Cytomegalovirus, herpes simplex virus
types 1 and 2, and human immunodeficiency virus were all
negative, but IgM antibody against hepatitis A was positive
(Table 1).
Therapy with a third-generation cephalosporin (cefotax-
ime), lactulose, ranitidine, and oral ampicillin was begun
according to our protocol for treating hepatic encephalop-
athy, and vitamin K (5 mg) was administered intravenously.
Plasmapheresis with fresh frozen plasma was performed in
two sessions that were 12 h apart. Twelve hours after her
admission to the hospital, the patient’s Hb and Hct levels
decreased to 6.1 g/dl and 19%, respectively. She required a
red cell transfusion because of progressive anemia. A
peripheral blood smear showed 79% neutrophils, target
cells, anisocytosis, and poikilocytosis. Her reticulocyte
count was 18.9%, her haptoglobin level was 25 mg/dl,
and the results of a direct Coombs’ test were negative.
Hemoglobin electrophoresis revealed 99.1% hemoglobin
A1 and 0.9% hemoglobin A2. A spot urine examination
showed two positive results (for hemoglobinuria and
bilirubinuria). Her G6PD level showed a low level of
Table 1 Laboratory findings
of patients




Variable Patient 1 Patient 2 nl values
Admission 8 h later Admission 12
h later
Hb, g/dl 8.5 5.1 9.8 6.1 12–15
WBC, ×109/l 26.1 30 23.9 4.5–11
Reticulocyte, % 6.75 18.9 0.5~1.5
LDH, U/l 5979 1570 180–430
Haptoglobulin, mg/dl 4 25
G6PD, U/g Hb 1.34 1.8 4.6–13.5
BUN, mg/dl 33 51 46 6.0–21
Creat, mg/dl 0.75 1.45 1.6
Uric acid, mg/dl 9.9 11 10.8 2.0–5.8
Total bilirubin, mg/dl 52.41 55.9 48 0.0–1.2
Direct bilirubin, mg/dl 32.12 32.17 31 0.0–0.3
Direct Coombs’ test Negative Negative Negative
Autoantibodies ANA, SMA, antidsDNA SMA Absent
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enzymatic activity (1.8 U/g Hb; normal range, 4.6–13.5 U/g
Hb). Two sessions of plasmapheresis were performed. She
was adequately hydrated, and her urine output remained
within normal limits. Her encephalopathy resolved, and her
bilirubin, BUN, and creatinine levels returned to values
within the normal range. The duration of her hospitalization
was 11 days. Six months after her discharge from the
hospital, her G6PD activity was re-evaluated, and the result
of the assay was below the normal range. Her SMA test
result was negative, and her hemoglobin level was within
the normal range.
Discussion
Infection with hepatitis A generally is believed to be self-
limited; however, it can produce effects that range from a
lack of symptoms to death from fulminant hepatitis [8].
Hemolytic anemia is an extrahepatic manifestation of viral
hepatitis, including hepatitis A. Although the results of
direct Coombs’ tests were negative, both patients reported
here had the presence of autoimmune antibodies such as
ANA, SMA, and antidsDNA. In genetically predisposed
individuals, infections could act as environmental triggers
inducing or promoting autoimmune disease [4]. It has been
suggested that acute hepatitis A virus infection induces
autoimmune hemolytic anemia [15]. Infection with hepatitis
A virus might have played a role in the acute hemolysis in
our patients. Nevertheless, during follow-up, no hemolytic
anemia was detected, and the autoimmune antibodies
disappeared. Except for plasmapheresis, our patients re-
ceived no specific treatment for autoimmune hemolytic
anemia. The proper role of plasmapheresis when treating
autoimmune hemolytic anemia remains uncertain [14].
Some authors believe that plasmapheresis helps stabilize
patients with fulminant hemolysis or improves responsive-
ness to transfusions. Available clinical data are limited to
case reports that do not always show improvement. For this
reason, we could not totally relate our patients’ acute
hemolysis to postinfectious autoimmune hemolytic anemia.
Berlin and associates [4] reported that in nonautoimmune
individuals with various infections, elevated titers of
autoantibodies could be detected by molecular mimicry of
microbial peptides similar to self-tissues. The transient
nature of the autoantibodies in our patients could be
explained by this.
Our patients had low levels of G6PD. Administration of
vitamin K, which is known to cause hemolysis in patients
with a G6PD deficiency, could have precipitated the
hemolysis. Hemolytic episodes are associated with acute
and chronic hepatitis; these episodes occur in patients with
viral hepatitis A and a G6PD deficiency [5, 6, 9]. Hepatitis
A also is prevalent in the Mediterranean area, and the
concomitant occurrence of those two relatively common
conditions (hepatitis A and G6PD deficiency) in the same
patient would therefore be expected. Chau and colleagues
[7] retrospectively studied 434 patients with acute hepatitis
and found that the overall incidence of acute hemolysis was
4% (17/434). In that series, 53% of the patients with
hemolysis had a G6PD deficiency.
The G6PD deficiency is an X-linked disorder. Most
heterozygous women and girls do not have clinical
hemolysis after exposure to oxidant stress. Rarely, the
majority of the erythrocytes are G6PD deficient in
heterozygous females, because of random inactivation of
the normal X chromosome [5]. The milder clinical
evolution seen in patient 2 could have been because the
patient was a heterozygous girl. She did not require
hemodialysis. Although she had encephalopathy on admis-
sion, she became conscious after two sessions of plasma-
pheresis. Her encephalopathy possibly was related to a high
serum ammonia level.
Because G6PD is the only way to generate a reduced
form of nicotinamide-adenine dinucleotide phosphate, a
substance that maintains the reduced form of glutathione
(which protects against oxidative damage) in cells, hemo-
lysis may develop in G6PD-deficient patients with viral
hepatitis A. Abnormally low levels of glutathione, which
revert to normal levels after a patient’s recovery, have been
identified during hepatitis infection [7]. The level of
glutathione, which is already low in patients who are
G6PD deficient, decreases further in people with infections,
including hepatitis [5, 11].
Kattamis and Tjortjatou [11] observed minor evidence of
hemolysis in 23% of patients with viral hepatitis who were
not G6PD deficient. However, they noted mild, moderate,
or severe hemolysis in 87% of G6PD-deficient persons.
They reported that their patients with acute viral hepatitis
with G6PD deficiency with or without hemolysis had
higher bilirubin values than did patients with viral hepatitis
without G6PD deficiency. Hemolysis was not always
associated with hyperbilirubinemia in their G6PD-deficient
patients. These investigators [11] suggested that a hepatic
factor (perhaps direct hepatic damage) rather than hemoly-
sis might be responsible for severe hyperbilirubinemia in
patients with a G6PD deficiency.
Similarly, Gotsman and Muszkat [9] reported that
patients with hepatitis A and a G6PD deficiency had a
more severe clinical presentation characterized by neuro-
logic deterioration, severe hemolysis, and a longer hospital
stay than did patients with hepatitis A without a G6PD
deficiency. These authors studied 200 patients with hepa-
titis A and found that 18 (9%) were G6PD deficient, and
that hemolysis occurred in 44% of the patients with a G6PD
deficiency. When compared with patients without a G6PD
deficiency who had the same infection, the G6PD-deficient
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patients had a higher-grade fever, leukocytosis, and higher
bilirubin level. The high bilirubin levels in patients with
G6PD deficiency and hepatitis A could not be entirely
explained by hemolysis, because both total and direct
bilirubin levels were statistically significantly higher in all
patients with G6PD deficiency, including those without
hemolysis. In patients with a G6PD deficiency, the
prothrombin time was statistically significantly longer than
that it was in controls. These authors suggest that the G6PD
enzyme deficiency might increase the severity of liver
damage.
The G6PD deficiency may have deleterious effects on
bilirubin metabolism. In a study by Morrow and colleagues
[13], severe (and primarily) direct hyperbilirubinemia in
patients with chronic hepatitis and a G6PD deficiency was
attributed to the direct disruption of bilirubin metabolism or
to direct damage to the liver. Hepatocellular damage and
cholestasis were revealed in the results of liver biopsy in
those patients.
In our two patients, clinical and laboratory findings (i.e.,
neurologic deterioration, severe hemolysis, high tempera-
ture, high leukocyte count, and elevated serum bilirubin
level) were consistent with the data in previous reports [9,
11, 13], and the direct fraction of bilirubin was higher than
the indirect fraction. We suggest that intravascular hemoly-
sis in the presence of liver disease may cause severe
hyperbilirubinemia, as the patients described in this report
demonstrate.
Although acute tubular necrosis leading to acute renal
failure and death has been reported in patients with acute
viral hepatitis A [6, 9, 10], significant renal dysfunction in
patients with that type of hepatitis is rare. Because of the
lack of controlled trials, the role of plasmapheresis in
preventing renal dysfunction has not been well established.
Although the hyperbilirubinemia in our first patient
responded to plasmapheresis, acute renal failure could not
be prevented, and hemodialysis was required.
In conclusion, we suggest that all patients with acute
viral hepatitis A and marked hyperbilirubinemia be care-
fully observed for hemolysis and subsequent renal dys-
function. Prophylactic measures against acute renal failure,
such as ensuring the patient’s high urinary output, correct-
ing fluid and electrolyte imbalances, and avoiding treatment
with nephrotoxic drugs, should be started early. Acute
hepatitis A associated with a G6PD deficiency should be
considered in the differential diagnosis of patients with
acute viral hepatitis and evidence of hemolysis. When
hemolytic anemia may be present, vitamin K administration
(which precipitates further hemolysis) should be postponed
until a G6PD deficiency has been ruled out. We suggest
that G6PD-deficient persons be considered for the hepatitis
A vaccine. Genetic screening for the G6PD phenotype
should be done to prevent such hemolytic episodes among
G6PD-deficient patients, particularly those who are of an
ethnic population in which this trait is reportedly more
prevalent. In addition to its other benefits, universal
vaccination against the hepatitis A virus is the most
effective strategy for preventing hepatitis-A-associated
hemolytic complications.
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